Research, Tests & Studies
Our guiding principle at intervention is to foster sustainable development through high-quality research. This is the energy behind the integrity we put in designing research protocols, recruiting participants, and disseminating our findings to our diverse audiences.
IVON-PP Trial
The IVON-PP Trial aims to determine the clinical effectiveness, tolerability, and safety of intravenous ferric carboxymaltose (intervention) versus oral ferrous sulphate (control) for treating moderate to severe iron deficiency anemia in postpartum women (population). To evaluate the acceptability and feasibility of intravenous ferric carboxymaltose in treating postpartum anemia in Nigeria.
IVON-IS Study
(Implementation Research for Intravenous Iron Use in Pregnant and Postpartum Nigerian Women)
This implementation research project aims to test options to strengthen routine screening for anaemia during and immediately after pregnancy and conditions necessary within the health system to deliver IV iron to pregnant and postpartum women with moderate to severe anaemia. The primary outcome of this study will be the implementation fidelity (effective coverage).
SPEC-AI Trial
(Screening for Peripartum Cardiomyopathy using Artificial Intelligence Nigeria)
The overall objective of this study is to determine if an artificial intelligence-enhanced electrocardiogram (AI-ECG) is an effective tool to screen for cardiomyopathy in a predominantly Black population of pregnant and postpartum women. Our long-term goal is to identify effective strategies for cardiomyopathy detection among pregnant and postpartum women so that appropriate interventions can be developed to decrease cardiomyopathy-related maternal mortality.
IVON Trial
The IVON Trial compares the effectiveness of intravenous ferric carboxymaltose (intervention) versus oral ferrous sulphate (control) for treating anaemia and IDA in pregnancy and to measure the acceptability, feasibility, fidelity (implementation outcomes) and the cost-effectiveness of intravenous iron among pregnant Nigerian women with moderate and severe anaemia, and IDA at 20–32 weeks’ gestation.
